Articles
21.06.2022
Seeking early advice from the EMA and multiple HTA...

Introduction Achieving access to patients for innovative treatments is becoming a significant challe...

Read more
Articles
09.06.2022
What is the New Innovative Medicines Fund and What...

The Innovative Medicines Fund launched on 7th June 2022 The Innovative Medicines Fund (IMF), which w...

Read more
Articles
07.06.2022
EU Joint HTA: What’s going on and what does it m...

EUnetHTA and the EU Joint HTA Process Originally set up in 2006, EUnetHTA was established to facilit...

Read more
Articles
25.05.2022
Is Saudi Arabia the indicator for change in the Mi...

Introduction For some manufacturers, launching in the Middle East and North Africa (MENA) is fraught...

Read more
Articles
17.05.2022
Is NRDL inclusion in China really the golden ticke...

Introduction As the most populous country in the world with 1.4 billion inhabitants, China has the p...

Read more
Articles
11.05.2022
How are countries in South-East Asia establishing ...

Introduction Health Technology Assessment (HTA) implementation has been historically slow in Asia co...

Read more
Articles
03.05.2022
What are the top 5 considerations to be aware of b...

Introduction: Brazil is a market of 210 million people Brazil is the largest country in South Americ...

Read more
Articles
28.04.2022
Regulators are giving early access to medicines, b...

Introduction Early Access Programs (EAPs) help to give people with life threatening or seriously deb...

Read more
Articles
25.04.2022
What do France’s ATU reforms mean for manufa...

Introduction On 1 July 2021, France made changes to its long-standing Authorization for Temporary Us...

Read more
Articles
19.04.2022
Could Brexit lead to earlier access to medicines f...

Introduction Following Brexit, regulatory oversight in the UK has switched from the European Medicin...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.